Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials

Cardiovascular Therapeutics

Volumn 33, Issue 6, 2015, Pages 338-346

  Bonsu, Kwadwo Osei ^a,b   Reidpath, Daniel Diamond ^a   Kadirvelu, Amudha ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

Author keywords

Adjusted indirect comparison; Heart failure; Hydrophilic statin; Lipophilic statin; Meta analysis

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PITAVASTATIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT;

ARTICLE; COMPARATIVE STUDY; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDROPHILICITY; INFLAMMATION; LIPOPHILICITY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84945970714     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12150     Document Type: Article

References (65)

1. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-248.
2. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-1491.
3. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988;77:721-730.
4. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995;92:1379-1382.
5. Kaneko K, Kanda T, Yamauchi Y, et al. C-Reactive protein in dilated cardiomyopathy. Cardiology 1999;91:215-219.
6. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-479.
7. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873.
8. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985.
9. Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013;9:303-319.
10. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
11. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Investig 1995;95:677-685.
12. Trochu JN, Mital S, Zhang X, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003;60:250-258.
13. Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol (1985) 2003;95:700-704.
14. Sola S, Mir MQS, Rajagopalan S, Helmy T, Tandon N, Khan BV. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Cardiac Fail 2005;11:607-612.
15. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-843.
16. Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Cardiac Fail 2007;13:1-7.
17. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359-363.
18. Zhang L, Zhang S, Jiang H, et al. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. Arch Med Res 2010;41:464-471.
19. Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J. Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 2011;34:117-123.
20. Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013;77:917-925.
21. Broch K, Askevold ET, Gjertsen E, et al. The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial. PLoS One 2014;9:e89732.
22. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GW. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-1716.
23. Zhang S, Zhang L, Sun A, Jiang H, Qian J, Ge J. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med 2011;22:478-484.
24. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-125.
25. Lee H-Y, Cho H-J, Kim H-Y, Jeon H-K, Shin JH, Kang S-M, Baek SH. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med 2014;29:754-763.
26. Tsutamoto T, Yamaji M, Kawahara C, Nishiyama K, Fujii M, Yamamoto T, Horie M. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail 2009;11:1195-1201.
27. Tsutamoto T, Sakai H, Ibe K, et al. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 2011;75:2160-2166.
28. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-691.
29. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011;150:325-331.
30. Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
31. Bonsu KO, Kadirvelu A, Reidpath DD. Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Syst Rev 2013;2:22.
32. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D, McQuay H. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
34. Ioannidis J, Patsopoulos N, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007;335:914-916.
35. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
37. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009;15:MS12-MS23.
38. Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy - 5-year follow-up. Lipids Health Dis 2013;12:47.
39. Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010;12:1345-1353.
40. Abulhul E, McDonald K, Martos R, et al. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther 2012;34:91-100.
41. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010;210:194-198.
42. Awwad O, El-Zahwy SS, Shawky A, Attia S. Short term statin treatment in idiopathic dilated cardiomyopathy. Egypt Heart J 2012;64:15-20.
43. Bauersachs J, Stork S, Kung M, et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007;37:852-859.
44. Erbs S, Beck EB, Linke A, et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling-results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol 2011;146:56-63.
45. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
46. Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther 2009;23:369-376.
47. Horwich TB, Middlekauff HR, Maclellan WR, Fonarow GC. Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail 2011;17:879-886.
48. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, Radovancevic B. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008;14:140-144.
49. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006;97:899-904.
50. Xie RQ, Cui W, Liu F, Yang C, Pei WN, Lu JC. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010;140:255-257.
51. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007;153:1055.e1051-1055.e1058.
52. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-1434.
53. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
54. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-1538.
55. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205-214.
56. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004;147:931-938.
57. Edwards SJ, Clarke MJ, Wordsworth S, Borrill J. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009;63:841-854.
58. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002;30:1158-1163.
59. Ford JS, Tayek JA. Lipophilicity and cardiovascular outcome in patients with CHF. Am Heart J 2008;156:e7; author reply e9.
60. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
61. Takagi H, Umemoto T. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: A meta-analysis of randomized trials. Int J Cardiol 2012;155:296-299.
62. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-428.
63. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61:455-463.
64. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004;110:412-418.
65. Lewandowski J, Symonides B, Gaciong Z, Siński M. The effect of statins on sympathetic activity: a meta-analysis. Clin Auton Res 2015;25:125-131.